HNSA.ST
Price:
$32.32
Market Cap:
$2.19B
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune di...[Read more]
Industry
Biotechnology
IPO Date
2007-10-17
Stock Exchange
STO
Ticker
HNSA.ST
According to Hansa Biopharma AB (publ)’s latest financial reports and current stock price. The company's current PE Ratio is -2.93. This represents a change of -20.00% compared to the average of -3.66 of the last 4 quarters.
The mean historical PE Ratio of Hansa Biopharma AB (publ) over the last ten years is -21.21. The current -2.93 PE Ratio has changed 1.28% with respect to the historical average. Over the past ten years (40 quarters), HNSA.ST's PE Ratio was at its highest in in the September 2023 quarter at -1.80. The PE Ratio was at its lowest in in the September 2018 quarter at -50.65.
Average
-21.21
Median
-18.00
Minimum
-50.14
Maximum
-1.66
Discovering the peaks and valleys of Hansa Biopharma AB (publ) PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 190.13%
Maximum Annual PE Ratio = -1.66
Minimum Annual Increase = -79.18%
Minimum Annual PE Ratio = -50.14
Year | PE Ratio | Change |
---|---|---|
2023 | -1.66 | -54.26% |
2022 | -3.62 | -49.77% |
2021 | -7.20 | -70.10% |
2020 | -24.09 | 158.47% |
2019 | -9.32 | -79.18% |
2018 | -44.76 | -10.74% |
2017 | -50.14 | 45.05% |
2016 | -34.57 | 190.13% |
2015 | -11.92 | -52.01% |
2014 | -24.83 | 111.59% |
The current PE Ratio of Hansa Biopharma AB (publ) (HNSA.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.16
5-year avg
-9.18
10-year avg
-21.21
Hansa Biopharma AB (publ)’s PE Ratio is less than Oncopeptides AB (publ) (-1.67), greater than ExpreS2ion Biotech Holding AB (publ) (-26.29), greater than BioInvent International AB (publ) (-7.23), greater than Zealand Pharma A/S (-75.45), less than Quantafuel ASA (-2.23),
Company | PE Ratio | Market cap |
---|---|---|
-1.67 | $438.37M | |
-26.29 | $53.66M | |
-7.23 | $2.96B | |
-75.45 | $60.80B | |
-2.23 | $1.77B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Hansa Biopharma AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Hansa Biopharma AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Hansa Biopharma AB (publ)'s PE Ratio?
How is the PE Ratio calculated for Hansa Biopharma AB (publ) (HNSA.ST)?
What is the highest PE Ratio for Hansa Biopharma AB (publ) (HNSA.ST)?
What is the 3-year average PE Ratio for Hansa Biopharma AB (publ) (HNSA.ST)?
What is the 5-year average PE Ratio for Hansa Biopharma AB (publ) (HNSA.ST)?
How does the current PE Ratio for Hansa Biopharma AB (publ) (HNSA.ST) compare to its historical average?